Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infusional FOLFOX Plus Camrelizumab and Apatinib Versus HAIC-FOLFOX Plus Camrelizumab and Apatinib for Hepatocellular Carcinoma
NCT06172205Phase 3Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jul 2023
- Primary completion
- Jul 2028
- Modality
- Immune Checkpoint Inhibitors, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, folinic acid, fluorouracil, camrelizumab and Rivoceranib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: 6-month Progression-Free Survival Rate and Hepatic Reserve Function Impairment Rate (ICG-15min) up to 3 years. Started Jul 2023; status: recruiting.
02
Drugs
oxaliplatinfolinic acidfluorouracilcamrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06172205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06172205.